NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...

Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...

Hundreds of people with aggressive blood cancer will be offered a groundbreaking one-off personalised therapy that ...

Mark Hoppus of Blink-182 has announced details of a US tour for his new memoir 'Fahrenheit-182'. Find the details here.

Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...

Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that ...

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside of their normal neighborhood -- known as the tertiary lymphoid structure -- where they become ...

Vontobel Holding Ltd. reduced its stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) by 23.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 9,467 shares of ...